Among current approaches, phenylboronic acid‐based formulations represent a leading strategy due to their reversible glucose‐binding capacity; these compounds activate insulin release upon hyperglycemia and automatically deactivate when glucose normalizes [223]. The gene discussed is INS; the disease is Hyperglycemia.